These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy. Lin X; Li F; Gu Q; Wang X; Zheng Y; Li J; Guan J; Yao C; Liu X Acta Biomater; 2022 Jul; 146():406-420. PubMed ID: 35470078 [TBL] [Abstract][Full Text] [Related]
65. [Immune suppressive cells in the tumor microenvironment of multiple myeloma]. Shimura Y Rinsho Ketsueki; 2023; 64(9):1099-1105. PubMed ID: 37899188 [TBL] [Abstract][Full Text] [Related]
66. Current progress in cancer immunotherapy based on natural killer cells. Bagheri Y; Barati A; Aghebati-Maleki A; Aghebati-Maleki L; Yousefi M Cell Biol Int; 2021 Jan; 45(1):2-17. PubMed ID: 32910474 [TBL] [Abstract][Full Text] [Related]
67. Nonviral genome engineering of natural killer cells. Robbins GM; Wang M; Pomeroy EJ; Moriarity BS Stem Cell Res Ther; 2021 Jun; 12(1):350. PubMed ID: 34134774 [TBL] [Abstract][Full Text] [Related]
68. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Campbell KS; Cohen AD; Pazina T Front Immunol; 2018; 9():2551. PubMed ID: 30455698 [TBL] [Abstract][Full Text] [Related]
69. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Guillerey C; Nakamura K; Vuckovic S; Hill GR; Smyth MJ Cell Mol Life Sci; 2016 Apr; 73(8):1569-89. PubMed ID: 26801219 [TBL] [Abstract][Full Text] [Related]
70. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Jiang H; Zhang W; Shang P; Zhang H; Fu W; Ye F; Zeng T; Huang H; Zhang X; Sun W; Man-Yuen Sze D; Yi Q; Hou J Mol Oncol; 2014 Mar; 8(2):297-310. PubMed ID: 24388357 [TBL] [Abstract][Full Text] [Related]
71. Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma. Nwangwu CA; Weiher H; Schmidt-Wolf IGH Hematol Oncol; 2017 Dec; 35(4):719-725. PubMed ID: 27430430 [TBL] [Abstract][Full Text] [Related]
73. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Naeimi Kararoudi M; Nagai Y; Elmas E; de Souza Fernandes Pereira M; Ali SA; Imus PH; Wethington D; Borrello IM; Lee DA; Ghiaur G Blood; 2020 Nov; 136(21):2416-2427. PubMed ID: 32603414 [TBL] [Abstract][Full Text] [Related]
74. Combination immune therapies to enhance anti-tumor responses by NK cells. Mentlik James A; Cohen AD; Campbell KS Front Immunol; 2013 Dec; 4():481. PubMed ID: 24391651 [TBL] [Abstract][Full Text] [Related]
75. Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion. Ryu D; Kim SJ; Hong Y; Jo A; Kim N; Kim HJ; Lee HO; Kim K; Park WY Clin Cancer Res; 2020 Feb; 26(4):935-944. PubMed ID: 31558476 [TBL] [Abstract][Full Text] [Related]
76. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301 [No Abstract] [Full Text] [Related]
77. [Research progress on immunotherapy based on NK cells for hepatocellular carcinoma]. Zhu X; Zhou Y; Zhu S Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Jan; 40(1):80-88. PubMed ID: 38246181 [TBL] [Abstract][Full Text] [Related]
78. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D. Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD Front Immunol; 2020; 11():40. PubMed ID: 32082316 [TBL] [Abstract][Full Text] [Related]
79. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Shi J; Tricot G; Szmania S; Rosen N; Garg TK; Malaviarachchi PA; Moreno A; Dupont B; Hsu KC; Baxter-Lowe LA; Cottler-Fox M; Shaughnessy JD; Barlogie B; van Rhee F Br J Haematol; 2008 Dec; 143(5):641-53. PubMed ID: 18950462 [TBL] [Abstract][Full Text] [Related]